---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-017285"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T10:33:05.312620+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biofrontera acquires U.S. rights to Ameluz/RhodoLED from Biofrontera AG; raises $11M via Series C preferred

## Summary
- Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG; will pay royalty of 12% or 15% based on $65M revenue threshold.
- Biofrontera AG receives 3,109 Series D Convertible Preferred shares (10% post-money equity stake) as part of consideration.
- Private placement of up to 11,000 Series C Preferred shares at $1,000 each for gross proceeds of up to $11.0M to fund the deal.
- Initial closing of $8.5M expected July 1, 2025; subsequent closing of $2.5M expected by September 30, 2025.
- Conversion and voting rights of both preferred series are subject to stockholder approval under Nasdaq rules.

## SEC filing metadata
- accession: 0001641172-25-017285
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000164117225017285/0001641172-25-017285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000164117225017285/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-017285
- JSON: https://secwatch.observer/filing/0001641172-25-017285.json
- Plain text: https://secwatch.observer/filing/0001641172-25-017285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.